Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 02.07.2020 | 09:57

Aladdin Healthcare Technologies SE discovers Life-Saving Drug Repurposed for Coronavirus and wins the World's Leading Data Mining Conference Cup

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous
02.07.2020 / 09:57
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies SE discovers Life-Saving Drug Repurposed for Coronavirus and wins the World's Leading Data Mining Conference Cup

- Already in February 2020, Aladdin's Knowledge Graph successfully ranked Dexamethasone as the number one candidate as repurposed drug to treat coronavirus

- Dexamethasone has recently been globally validated as the 'first life-saving drug' to fight Coronavirus

- Aladdin will present its medical paper about the COVID-19 centered Knowledge Graph at the ACM SIGKDD annual conference, the world premier forum for data mining

BERLIN/LONDON, July 2, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, successfully predicted through its proprietary Knowledge Graph dexamethasone as the most likely repurposed drug to treat coronavirus infection, already in February this year. Aladdin made an advanced discovery in the coronavirus treatment far in advance of the European outbreak of the coronavirus.

After submitting its research paper in May this year to the Association for Computing Machinery's Special Interest Group on Knowledge Discovery and Data Mining (ACM SIGKDD), the world-renowned organisation for data mining and data science, Aladdin has now been selected as one of the winners among thousands of participants around the world. Aladdin was selected to participate in the ACM SIGKDD annual conference in August this year, in San Diego CA, with its medical paper to be published on TCBB, a top AI biomedical journal hosted by the conference. This displays the significant power of Aladdin's Knowledge Graph to assist and accelerate the drug discovery process.

Early this year, Aladdin's team of researchers merged and analysed over 51,000 medical articles related to the coronavirus, by using Artificial Intelligence and advanced text mining techniques with the purpose of creating a biomedical Knowledge Graph centered on COVID-19 and to find the most suitable medical compounds to combat it. Dexamethasone, a low-dose steroid treatment, was ranked at the first place of potential drug compounds.

"We are delighted to have been selected to take part in the ACM SIGKDD annual conference this year. This is our chance to present Aladdin's breakthrough in the drug development, especially in such an exceptional environment like the current one shaped by the coronavirus emergency," says Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, "Our discovery came up even before the real outbreak of the pandemic in Europe, which shows how far ahead we were and still are in the development of new potential drugs and their repurposing."

The ACM SIGKDD conference represents a chance to once again put Aladdin's expertise to the use of medical research and to create new strong connections with other relevant players in the biomedical field. Taking part at such an important event underlines the ability of Aladdin reaching great breakthroughs and work with major international partners.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link:

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330

02.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Deutschlands führendes Wohnungsunternehmen baut erneuerbare Energie weiter aus: Vonovia bestückt 30.000 Dächer mit Photovoltaik-Anlagen

21. September 2021, 09:58

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

q.beyond AG

Original-Research: q.beyond AG (von Montega AG): Kaufen

21. September 2021